APG808 vs dupilumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: IL-4R-alpha · full Chronic Obstructive Pulmonary Disease pipeline

APG808

Developed by Apogee Therapeutics under a licence from Paragon Therapeutics

monoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

dupilumab · Dupixent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Chronic Obstructive Pulmonary Diseasemonoclonal antibody
Partial signal

NCT03930732 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 939 participants, and its primary clinical endpoint was met: dupilumab significantly reduced moderate or severe COPD exacerbations over 52 weeks. The registry does not report the power or sample-size calculation needed to establish that the trial was adequately powered, so the evidence is graded as moderate rather than strong.

Next expected readout: July 2028 · NCT07587658 (registry estimate)

Reported efficacy

Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.295 Exacerbation per participant-year (95% CI 1.048 to 1.6) | Dupilumab 300 mg q2w 0.859 Exacerbation per participant-year (95% CI 0.699 to 1.057) (met)

Result source: NCT04456673

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAPG808dupilumab
Moderate or severe exacerbations, annualised rate—Not reported0.8 vs 1.0−0.2 vs placebo300 mg q2w · wk 52 · n 468NCT03930732
1 other result
  • 0.9 vs 1.3 300 mg q2w · wk 52 · n 470 · Phase 3 · primary NCT04456673
Trough FEV1, change—Not reported—Not reported
SGRQ total, change—Not reported-9.7 vs -6.4−3.4 vs placebo300 mg q2w · wk 52 · n 456NCT03930732
1 other result
  • -9.8 vs -6.4 300 mg q2w · wk 52 · n 350 · Phase 3 · secondary NCT04456673
TDI focal score—Not reported—Not reported

Moderate or severe exacerbations, annualised rate

APG808
—Not reported
dupilumab
0.8 vs 1.0−0.2 vs placebo300 mg q2w · wk 52 · n 468NCT03930732
1 other result
  • 0.9 vs 1.3 300 mg q2w · wk 52 · n 470 · Phase 3 · primary NCT04456673

Trough FEV1, change

APG808
—Not reported
dupilumab
—Not reported

SGRQ total, change

APG808
—Not reported
dupilumab
-9.7 vs -6.4−3.4 vs placebo300 mg q2w · wk 52 · n 456NCT03930732
1 other result
  • -9.8 vs -6.4 300 mg q2w · wk 52 · n 350 · Phase 3 · secondary NCT04456673

TDI focal score

APG808
—Not reported
dupilumab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

APG808: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. APG808: 0 of 4 rows · dupilumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdupilumab
Dropout rate
6%300 mg q2wa
NCT03930732 · Phase 3
show 1 more result
8.9%300 mg q2w
NCT04456673 · Phase 3
Discontinued due to AEs
1.5%300 mg q2wa
NCT03930732 · Phase 3
show 1 more result
3%300 mg q2w
NCT04456673 · Phase 3
Serious AEs
13.9%300 mg q2wa
NCT03930732 · Phase 3
show 1 more result
13.9%300 mg q2w
NCT04456673 · Phase 3
Most frequent reported AEs
300 mg q2wa
nasopharyngitis 9.6% (placebo 9.6%)
headache 8.1% (placebo 7%)
upper respiratory tract infection 7.9% (placebo 9.8%)
NCT03930732 · Phase 3
show 1 more result
300 mg q2w
covid-19 9.6% (placebo 7.8%)
headache 7.9% (placebo 6.3%)
nasopharyngitis 6.8% (placebo 6%)
NCT04456673 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

dupilumab

Moderate or Severe Exacerbation Rate Annualized 0.776 vs 1.01 placebo per year @ 52wk300 mg q2w
event rate · per year
NCT03930732 · Phase 3
show 1 more result
0.859 vs 1.295 placebo per year @ 52wk300 mg q2w
NCT04456673 · Phase 3
FEV1 0.16 vs 0.077 placebo L @ 12wk300 mg q2w
absolute change · L
NCT03930732 · Phase 3
show 31 more results
0.153 vs 0.07 placebo L @ 52wk300 mg q2w
NCT03930732 · Phase 3
0.232 vs 0.108 placebo L @ 12wk300 mg q2w
NCT03930732 · Phase 3
0.247 vs 0.12 placebo L @ 52wk300 mg q2w
NCT03930732 · Phase 3
0.159 vs 0.075 placebo L @ 2wk300 mg q2w
NCT03930732 · Phase 3
0.163 vs 0.069 placebo L @ 4wk300 mg q2w
NCT03930732 · Phase 3
0.149 vs 0.069 placebo L @ 8wk300 mg q2w
NCT03930732 · Phase 3
0.17 vs 0.068 placebo L @ 24wk300 mg q2w
NCT03930732 · Phase 3
0.155 vs 0.072 placebo L @ 36wk300 mg q2w
NCT03930732 · Phase 3
0.176 vs 0.089 placebo L @ 44wk300 mg q2w
NCT03930732 · Phase 3
0.158 vs 0.071 placebo L @ 2wk300 mg q2w
NCT03930732 · Phase 3
0.158 vs 0.08 placebo L @ 4wk300 mg q2w
NCT03930732 · Phase 3
0.153 vs 0.077 placebo L @ 8wk300 mg q2w
NCT03930732 · Phase 3
0.156 vs 0.084 placebo L @ 12wk300 mg q2w
NCT03930732 · Phase 3
0.169 vs 0.072 placebo L @ 24wk300 mg q2w
NCT03930732 · Phase 3
0.155 vs 0.072 placebo L @ 36wk300 mg q2w
NCT03930732 · Phase 3
0.138 vs 0.058 placebo L @ 52wk300 mg q2w
NCT03930732 · Phase 3
0.139 vs 0.057 placebo L @ 12wk300 mg q2w
NCT04456673 · Phase 3
0.115 vs 0.054 placebo L @ 52wk300 mg q2w
NCT04456673 · Phase 3
0.108 vs 0.072 placebo L @ 2wk300 mg q2w
NCT04456673 · Phase 3
0.132 vs 0.077 placebo L @ 4wk300 mg q2w
NCT04456673 · Phase 3
0.133 vs 0.069 placebo L @ 8wk300 mg q2w
NCT04456673 · Phase 3
0.154 vs 0.064 placebo L @ 24wk300 mg q2w
NCT04456673 · Phase 3
0.117 vs 0.068 placebo L @ 36wk300 mg q2w
NCT04456673 · Phase 3
0.154 vs 0.065 placebo L @ 44wk300 mg q2w
NCT04456673 · Phase 3
0.101 vs 0.082 placebo L @ 2wk300 mg q2w
NCT04456673 · Phase 3
0.126 vs 0.098 placebo L @ 4wk300 mg q2w
NCT04456673 · Phase 3
0.147 vs 0.083 placebo L @ 8wk300 mg q2w
NCT04456673 · Phase 3
0.136 vs 0.064 placebo L @ 12wk300 mg q2w
NCT04456673 · Phase 3
0.152 vs 0.081 placebo L @ 24wk300 mg q2w
NCT04456673 · Phase 3
0.131 vs 0.07 placebo L @ 36wk300 mg q2w
NCT04456673 · Phase 3
0.127 vs 0.059 placebo L @ 52wk300 mg q2w
NCT04456673 · Phase 3
SGRQ Total -9.732 vs -6.369 placebo score @ 52wk300 mg q2w
absolute change · score
NCT03930732 · Phase 3
show 1 more result
-9.816 vs -6.444 placebo score @ 52wk300 mg q2w
NCT04456673 · Phase 3
SGRQ 51.5% (n=468) vs 43.1% (n=471) placebo @ 52wk300 mg q2w
responder rate · % of participants
NCT03930732 · Phase 3
show 1 more result
51.4% (n=362) vs 46.5% (n=359) placebo @ 52wk300 mg q2w
NCT04456673 · Phase 3
E-RS Total -2.694 vs -1.558 placebo score @ 52wk300 mg q2w
absolute change · score
NCT03930732 · Phase 3
FEF 25-75% 0.11 vs 0.065 placebo L @ 2wk300 mg q2w
absolute change · L
NCT03930732 · Phase 3
show 22 more results
0.115 vs 0.066 placebo L @ 4wk300 mg q2w
NCT03930732 · Phase 3
0.114 vs 0.069 placebo L @ 8wk300 mg q2w
NCT03930732 · Phase 3
0.137 vs 0.076 placebo L @ 12wk300 mg q2w
NCT03930732 · Phase 3
0.142 vs 0.08 placebo L @ 24wk300 mg q2w
NCT03930732 · Phase 3
0.132 vs 0.087 placebo L @ 36wk300 mg q2w
NCT03930732 · Phase 3
0.162 vs 0.091 placebo L @ 44wk300 mg q2w
NCT03930732 · Phase 3
0.135 vs 0.088 placebo L @ 52wk300 mg q2w
NCT03930732 · Phase 3
0.135 vs 0.074 placebo L @ 2wk300 mg q2w
NCT03930732 · Phase 3
0.144 vs 0.087 placebo L @ 4wk300 mg q2w
NCT03930732 · Phase 3
0.144 vs 0.083 placebo L @ 8wk300 mg q2w
NCT03930732 · Phase 3
0.161 vs 0.089 placebo L @ 12wk300 mg q2w
NCT03930732 · Phase 3
0.169 vs 0.093 placebo L @ 24wk300 mg q2w
NCT03930732 · Phase 3
0.161 vs 0.093 placebo L @ 36wk300 mg q2w
NCT03930732 · Phase 3
0.153 vs 0.093 placebo L @ 52wk300 mg q2w
NCT03930732 · Phase 3
0.103 vs 0.057 placebo L @ 2wk300 mg q2w
NCT04456673 · Phase 3
0.114 vs 0.056 placebo L @ 4wk300 mg q2w
NCT04456673 · Phase 3
0.134 vs 0.059 placebo L @ 8wk300 mg q2w
NCT04456673 · Phase 3
0.137 vs 0.066 placebo L @ 12wk300 mg q2w
NCT04456673 · Phase 3
0.147 vs 0.051 placebo L @ 24wk300 mg q2w
NCT04456673 · Phase 3
0.128 vs 0.073 placebo L @ 36wk300 mg q2w
NCT04456673 · Phase 3
0.154 vs 0.053 placebo L @ 44wk300 mg q2w
NCT04456673 · Phase 3
0.122 vs 0.065 placebo L @ 52wk300 mg q2w
NCT04456673 · Phase 3
Time to First Moderate or Severe Exacerbation 0.01 vs 0 placebo months @ 12wk300 mg q2w
time to event · months
NCT03930732 · Phase 3 · converted to months from 0.024 weeks as posted
show 7 more results
0.01 vs 0.01 placebo months @ 24wk*300 mg q2w
NCT03930732 · Phase 3 · converted to months from 0.034 weeks as posted
0.01 vs 0.01 placebo months @ 36wk*300 mg q2w
NCT03930732 · Phase 3 · converted to months from 0.039 weeks as posted
0.01 vs 0.01 placebo months @ 52wk*300 mg q2w
NCT03930732 · Phase 3 · converted to months from 0.043 weeks as posted
0.02 vs 0.04 placebo months @ 12wk*300 mg q2w
NCT04456673 · Phase 3 · converted to months from 0.108 weeks as posted
0.05 vs 0.06 placebo months @ 24wk*300 mg q2w
NCT04456673 · Phase 3 · converted to months from 0.206 weeks as posted
0.07 vs 0.08 placebo months @ 36wk*300 mg q2w
NCT04456673 · Phase 3 · converted to months from 0.292 weeks as posted
0.08 vs 0.1 placebo months @ 52wk*300 mg q2w
NCT04456673 · Phase 3 · converted to months from 0.361 weeks as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: APG808's landscape · dupilumab's landscape